Dr. Seth M. Pollack, MD
Hematology & Oncology (Hematology & Oncology Physician)
676 N Saint Clair St Ste 850
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- George Washington University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 225
Licensed in Washington since 2008, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: George Washington University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036154157 (first issued 2020; active) -
Medical Oncology Physician
WA license MD60006970 (first issued 2008; expired)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Mchenry Mchenry, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 225
- Services billed
- 49,378
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 10,500 | 14 |
| Injection, nivolumab, 1 mg | 6,680 | 12 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 4,500 | 20 |
| Injection, fosaprepitant, 1 mg | 4,200 | 22 |
| Injection, pembrolizumab, 1 mg | 2,800 | 13 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 2,340 | 30 |
| Injection, bortezomib, 0.1 mg | 593 | 14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 420 | 36 |
| Injection, palonosetron hcl, 25 mcg | 320 | 30 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 250 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 39 payments worth $43,736 in total to this clinician.
| Springworks Therapeutics, Inc. | $25,773 |
|---|---|
| Deciphera Pharmaceuticals Inc. | $13,533 |
| EMD Serono, Inc. | $4,275 |
| Daiichi Sankyo Inc. | $126 |
| Ipsen Biopharmaceuticals, Inc | $29.50 |
| Compensation for services other than consulting (speaking, faculty) | $36,034 |
|---|---|
| Consulting Fee | $4,275 |
| Travel and Lodging | $2,222 |
| Food and Beverage | $1,205 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK; ROMVIMZA · ONCOLOGY | $7,344 |
| Springworks Therapeutics, Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $4,888 |
| Springworks Therapeutics, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $4,888 |
| EMD Serono, Inc. Oct 1, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,275 |
| Springworks Therapeutics, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Springworks Therapeutics, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Springworks Therapeutics, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Deciphera Pharmaceuticals Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,125 |
| Springworks Therapeutics, Inc. Feb 12, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $1,594 |
| Springworks Therapeutics, Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $1,594 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $625 |
| Springworks Therapeutics, Inc. Oct 30, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Springworks Therapeutics, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $4,888 |
| Springworks Therapeutics, Inc. Oct 22, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to SIOUX FALLS, SD | $170 |
| Springworks Therapeutics, Inc. Oct 9, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to SIOUX FALLS, SD · in-kind | $547 |
| Springworks Therapeutics, Inc. Oct 9, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to SIOUX FALLS, SD · in-kind | $168 |
| EMD Serono, Inc. Oct 1, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $4,275 |
| Deciphera Pharmaceuticals Inc. Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) ROMVIMZA · ONCOLOGY | $1,563 |
| Springworks Therapeutics, Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $4,888 |
| Springworks Therapeutics, Inc. Jun 19, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to BUFFALO, NY · in-kind | $667 |
| Springworks Therapeutics, Inc. Jun 19, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to BUFFALO, NY · in-kind | $242 |
| Springworks Therapeutics, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Springworks Therapeutics, Inc. Jun 4, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to NAPERVILLE, IL | $59.07 |
| Springworks Therapeutics, Inc. Jun 4, 2025 | Travel and Lodging OGSIVEO · DESMOID TUMORS · travel to NAPERVILLE, IL | $52.64 |
| Deciphera Pharmaceuticals Inc. May 13, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK · ONCOLOGY | $3,125 |
| Deciphera Pharmaceuticals Inc. May 13, 2025 | Travel and Lodging QINLOCK · ONCOLOGY · travel to CHICAGO, IL | $40.80 |
| Springworks Therapeutics, Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $1,594 |
| Springworks Therapeutics, Inc. Apr 17, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $850 |
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) QINLOCK; ROMVIMZA · ONCOLOGY | $7,344 |
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging QINLOCK; ROMVIMZA · ONCOLOGY · travel to CHICAGO, IL | $86.07 |
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging QINLOCK; ROMVIMZA · ONCOLOGY · travel to CHICAGO, IL | $64.94 |
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging QINLOCK; ROMVIMZA · ONCOLOGY · travel to CHICAGO, IL | $62.42 |
| Deciphera Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging QINLOCK; ROMVIMZA · ONCOLOGY · travel to CHICAGO, IL | $61.88 |
| Springworks Therapeutics, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $3,188 |
| Springworks Therapeutics, Inc. Feb 12, 2025 | Compensation for services other than consulting (speaking, faculty) OGSIVEO · DESMOID TUMORS | $1,594 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $626,669 in research payments for these studies, mostly to the institutions running them.
- XL092 in Bone, TAS, LMS
Exelixis Inc. - An Analysis of Nectin-4 Expression in Soft Tissue Sarcoma
Astellas Pharma Global Development - A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
Ptc Therapeutics, Inc. · Terminated · NCT05269355 - Observational study evaluating the long-term safety and efficacy of avapritinib in the first-linetreatment of patients with platelet-derived growth factor receptor alpha (PDGFRA) D842Vmutatedgastrointestinal stromal t…
Blueprint Medicines Corporation - Observational study evaluating the long-term safety and efficacy of avapritinib in the first-linetreatment of patients with platelet-derived growth factor receptor alpha (PDGFRA) D842Vmutatedgastrointestinal stromal t…
Sanofi US Services Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.